Articles tagged with Lymphoma
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers have discovered a gene, Irx5, that enables blood cancer cells to evade treatment by boosting survival protein levels. By activating specific genes using CRISPR activation tool Partita, the team also identified new potential treatment targets for aggressive lymphoma.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
Mantle cell lymphoma treatment may be improved by considering a patient's biology and risk level, rather than age alone. High-risk patients can be identified at diagnosis and treated with targeted therapies, while low-risk patients may receive less intensive treatment.
The Josep Carreras Institute has joined BLOODPAC to advance liquid biopsy research and clinical implementation. As a member, the Institute will collaborate with leading partners to develop standards, validation protocols, and access the BLOODPAC Portal for knowledge sharing.
Researchers at MSK have identified a protein called integrin alpha-5 as a key driver of lung metastasis across several cancer types. A new three-drug combination that includes epcoritamab, rituximab, and lenalidomide is effective in almost all patients newly diagnosed with follicular lymphoma, offering a potential alternative to chemot...
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
A new study suggests that younger, less genetically matched donors can produce encouraging outcomes for blood cancer patients. Researchers found that carefully selected mismatched donors can produce favorable outcomes, potentially widening access to a potentially lifesaving transplant.
A new blood test, ADLiB, combines genetic clues with machine learning to identify patients most likely to have lymphoma. The platform analyzes cell-free DNA and prioritizes patients who need a tissue biopsy, helping clinicians diagnose the disease more quickly.
A new study published in JNCCN finds that a cost-effective education program targeting survivors and their doctors can increase screening rates for skin cancer. The study showed that practical solutions can close the gap between elevated risks and low screening rates, especially after transitioning out of specialty care.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
Researchers have developed spatialproteomics, an open-source software package that makes it easier to analyze complex tissue images. This framework guides users from raw microscopy images through cell segmentation, annotation, and spatial analysis, standardizing workflows and enabling more efficient and reproducible results.
Research reveals that patients' inherited genetic variants can impact the benefits and toxicity of CAR-T cell therapy for blood cancers. Variants in genes such as STXBP2, ADAMTSL3, and PTPN22 were found to correlate with treatment-related toxicity or enhanced therapeutic activity.
Elaine S. Jaffe, a distinguished investigator at the NCI Center for Cancer Research, has transformed our understanding of lymphoid malignancies through her groundbreaking research. Her work has led to significant advancements in disease classifications, diagnosis, and treatment.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
A new study has identified molecular tumor characteristics that distinguish between different subtypes of diffuse large B-cell lymphoma (DLBCL). The findings suggest that tumors from high-risk patients, referred to as PG4 proteogenotype, are characterized by specific genetic mutations and protein patterns. These characteristics can hel...
A two-year fixed-duration triplet therapy of pirtobrutinib, venetoclax, and rituximab improves progression free survival for patients with relapsed/refractory CLL compared to standard therapy. Peripheral blood undetectable minimal residual disease rates are higher in patients receiving the triplet therapy.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Researchers have tested a new experimental cancer drug called gamitrinib in its first-in-human study. Gamitrinib is designed to target the mitochondria of cancer cells, where it can disrupt their energy systems.
The University of Cologne's researchers will continue to work on innovative treatments for lymph node cancer and study plant responses to environmental changes. The Collaborative Research Centres have received a total of approximately €39 million in funding, highlighting the university's strength in collaborative research.
Researchers identify genetic syndrome where unusually long telomeres predispose individuals to lymphoma and other cancers. Inherited loss-of-function mutations in the POT1 gene disrupt normal aging of lymphocytes, allowing cancer-associated changes to accumulate over time.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
A new study found that targeted maternal screening can prevent adult T-cell leukemia/lymphoma, a rare and aggressive cancer caused by human T-cell leukemia virus type 1. The research identified high disease rates among non-Hispanic Caribbean-born US residents, particularly in Florida and New York.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
Hodgkin lymphoma cells are immune cells stuck in an 'identity crisis,' unable to mature into functional plasma cells. The team discovered that these cells downregulate key B cell features and upregulate proteins to make them more like plasma cells, but not completely functioning as such.
Researchers discovered that HDAC7 plays a dual role in immune system development and cancer progression. Restoring HDAC7 in cancer cells can slow or stop tumor growth, offering new hope for diagnosis and treatment.
This study reveals that lymphoma cells exhibit organotropism based on their germ-layer origin, with different mutations affecting migration patterns and survival. The research provides insights into the molecular basis of tumor invasion and metastasis, offering a new perspective for personalized cancer treatment.
Researchers developed an interpretable machine learning algorithm, scOMM, to classify cell types consistently across different single-cell methods. The integration strategies and scOMM establish a robust approach for cell atlas generation in complex tissues, leading to the discovery of previously undetected rare cell types.
A new study from the University of Missouri identified over 10 genetic or molecular markers that predict follicular lymphoma relapse early, allowing for targeted surveillance testing. This could improve patient outcomes, reduce unnecessary imaging tests, and lower healthcare costs.
The Josep Carreras Leukaemia Research Institute is joining forces with the Chinese Institute of Hematology and Blood Diseases Hospital to advance blood cancer research. The partnership aims to develop joint translational research programmes and accelerate the development of curative therapies for patients with blood cancers.
Researchers find that rare stromal cells are responsible for maintaining immune cell organization in healthy lymph nodes. However, in aggressive lymphomas, this process breaks down due to a self-reinforcing inflammatory cycle, leading to tissue collapse and poorer outcomes.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
A new analysis shows that 42% of treated patients were functionally cured, marking a game-changer for an incurable disease. Recurrence rates declined drastically over time, from 6.8% in the first five years to 0.6% between 15 and 20 years.
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...
A case report investigates a woman's development of acute lymphoblastic leukemia and lymphoblastic lymphoma after receiving her second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, highlighting potential genetic and molecular mechanisms involved in disease pathogenesis.
CAR T-cell therapy is now available for eligible primary CNS lymphoma patients, thanks to Dana-Farber-led research. The FDA label update removes a prior exclusion and may expand treatment options for relapsed or refractory patients.
A team of researchers at VCU Massey Comprehensive Cancer Center has discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. The study found that RBF4...
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
Researchers at Kanazawa University have developed a new combination therapy that combines CAR-T cell therapy with a SUMOylation inhibitor, which effectively suppresses MYC activity and slows the growth of Burkitt's lymphoma cells. The approach extends survival rates in mouse models by up to 80%.
A new study reveals that mature B cells temporarily gain plasticity during the antibody-making process, which could explain how many lymphomas develop from mature B cells. Researchers discovered that this epigenetic change is tightly regulated and can be hijacked by specific mutations to promote lymphomagenesis.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
A global study found that patients with mature nodal T-cell lymphoma who relapsed within 12 months of initial treatment had worse survival outcomes, but improved survival when treated with targeted therapies instead of chemotherapy. The results suggest the need for personalized treatment strategies for high-risk patients.
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
A new trial shows pirtobrutinib to be more effective than bendamustine plus rituximab in treating previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug demonstrated improved survival rates, a favorable safety profile, and lower adverse event rates compared to the standard treatment.
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
A study found that measuring a patient's absolute lymphocyte count can predict their response to CAR T-cell therapy for non-Hodgkin lymphoma. Patients with higher lymphocyte counts and faster increases tend to have better outcomes, including progression-free survival and overall survival.
A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...
A new study finds that most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than intensive chemotherapy. The R-CHOP regimen has shown strong four-year survival rates for THRLBCL patients without significant side effects.
A new study presented at ASH 2025 suggests that a virtual program focusing on diet and exercise can help reduce the severity of side effects associated with lymphoma treatment. The program, LIFE-L, showed significant improvements in symptoms such as anxiety, depression, pain, fatigue, and constipation among participants.
A new study by University of Texas M.D. Anderson Cancer Center researchers identified CD40 overexpression as a potential biomarker associated with improved overall survival in angioimmunoblastic T cell lymphoma (AITL). This discovery could lead to therapeutic strategies to improve outcomes for this challenging disease.
A new study shows that adding epcoritamab to standard second-line therapy significantly improves follicular lymphoma outcomes, including a nearly 80% reduction in risk of death or disease progression. The treatment was also found to be effective for patients who received it on an outpatient basis.
The TRANSCEND FL trial demonstrates the effectiveness of lisocabtagene maraleucel in achieving durable remissions and favorable safety profiles in patients with relapsed or refractory follicular lymphoma. The therapy produced a 97% overall response rate, with most patients remaining in remission after three years.
A new study presented at the 2025 American Society of Hematology meeting revealed that subtle disruptions in genome architecture can predispose individuals to lymphoma. The research found that damaged 3D genome architecture can silence key tumor suppressor genes, creating fertile ground for malignancy.
Follicular lymphoma is a complex cancer with an unpredictable clinical course, prompting the need for innovative diagnostic tools and treatment strategies. An international alliance, ERADICATE, aims to address this challenge through AI-powered analysis, genomics, and immunology research.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.